Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EBT (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBT for 8 consecutive years, with $12.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 154.47% to $12.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.3 million through Dec 2025, down 132.9% year-over-year, with the annual reading at -$49.3 million for FY2025, 132.9% down from the prior year.
  • EBT for Q4 2025 was $12.9 million at Precision Biosciences, up from -$20.0 million in the prior quarter.
  • The five-year high for EBT was $25.4 million in Q2 2024, with the low at -$30.7 million in Q4 2021.
  • Average EBT over 5 years is -$11.5 million, with a median of -$13.8 million recorded in 2022.
  • The sharpest move saw EBT soared 1564.8% in 2024, then tumbled 582.47% in 2025.
  • Over 5 years, EBT stood at -$30.7 million in 2021, then surged by 65.3% to -$10.7 million in 2022, then decreased by 28.0% to -$13.6 million in 2023, then crashed by 74.05% to -$23.7 million in 2024, then surged by 154.47% to $12.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $12.9 million, -$20.0 million, and -$21.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.